guest ::
| Home > Publications Database > Overlap between age-at-onset and disease-progression determinants in Huntington disease. > print |
| Home > Publications Database > Overlap between age-at-onset and disease-progression determinants in Huntington disease. > print |
| 001 | 140098 | ||
| 005 | 20240321220737.0 | ||
| 024 | 7 | _ | |a 10.1212/WNL.0000000000005690 |2 doi |
| 024 | 7 | _ | |a pmid:29743208 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC5996832 |2 pmc |
| 024 | 7 | _ | |a 0028-3878 |2 ISSN |
| 024 | 7 | _ | |a 1526-632X |2 ISSN |
| 024 | 7 | _ | |a altmetric:40937168 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-06420 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Aziz, Ahmad |0 P:(DE-2719)2812578 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Overlap between age-at-onset and disease-progression determinants in Huntington disease. |
| 260 | _ | _ | |a [S.l.] |c 2018 |b Ovid |
| 264 | _ | 1 | |3 online |2 Crossref |b Ovid Technologies (Wolters Kluwer Health) |c 2018-05-09 |
| 264 | _ | 1 | |3 print |2 Crossref |b Ovid Technologies (Wolters Kluwer Health) |c 2018-06-12 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1592235819_17956 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a A fundamental but still unresolved issue regarding Huntington disease (HD) pathogenesis is whether the factors that determine age at onset are the same as those that govern disease progression. Because elucidation of this issue is crucial for the development as well as optimal timing of administration of novel disease-modifying therapies, we aimed to assess the extent of overlap between age-at-onset and disease-progression determinants in HD.Using observational data from Enroll-HD, the largest cohort of patients with HD worldwide, in this study we present, validate, and apply an intuitive method based on linear mixed-effect models to quantify the variability in the rate of disease progression in HD.A total of 3,411 patients with HD met inclusion criteria. We found that (1) about two-thirds of the rate of functional, motor, and cognitive progression in HD is determined by the same factors that also determine age at onset, with CAG repeat-dependent mechanisms having by far the largest effect; (2) although expanded HTT CAG repeat size had a large influence on average body weight, the rate of weight loss was largely independent of factors that determine age at onset in HD; and (3) about one-third of the factors that determine the rate of functional, motor, and cognitive progression are different from those that govern age at onset and need further elucidation.Our findings imply that targeting of CAG repeat-dependent mechanisms, for example through gene-silencing approaches, is likely to affect the rate of functional, motor, and cognitive impairment, but not weight loss, in manifest HD mutation carriers. |
| 536 | _ | _ | |a 345 - Population Studies and Genetics (POF3-345) |0 G:(DE-HGF)POF3-345 |c POF3-345 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 2 | |a Age of Onset |2 MeSH |
| 650 | _ | 2 | |a Disease Progression |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Huntington Disease: epidemiology |2 MeSH |
| 650 | _ | 2 | |a Huntington Disease: genetics |2 MeSH |
| 650 | _ | 2 | |a Huntington Disease: pathology |2 MeSH |
| 700 | 1 | _ | |a van der Burg, Jorien M M |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Tabrizi, Sarah J |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Landwehrmeyer, G Bernhard |0 P:(DE-HGF)0 |b 3 |
| 773 | 1 | 8 | |a 10.1212/wnl.0000000000005690 |b : Ovid Technologies (Wolters Kluwer Health), 2018-05-09 |n 24 |p e2099-e2106 |3 journal-article |2 Crossref |t Neurology |v 90 |y 2018 |x 0028-3878 |
| 773 | _ | _ | |a 10.1212/WNL.0000000000005690 |g Vol. 90, no. 24, p. e2099 - e2106 |0 PERI:(DE-600)1491874-2 |n 24 |q 90:24 |t Neurology |v 90 |y 2018 |x 0028-3878 |
| 856 | 7 | _ | |2 Pubmed Central |u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996832 |
| 909 | C | O | |o oai:pub.dzne.de:140098 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2812578 |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-345 |2 G:(DE-HGF)POF3-300 |v Population Studies and Genetics |x 0 |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a Allianz-Lizenz |0 StatID:(DE-HGF)0410 |2 StatID |d 2022-11-12 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-12 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEUROLOGY : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-12 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b NEUROLOGY : 2021 |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-2719)1012001 |k AG Breteler 1 |l Population Health Sciences |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1012001 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|